Biotherapies for Life
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative therapies. The company offers the broadest range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. CSL Behring’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. The company operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 22,000 people, and delivers its life-saving therapies to people in more than 60 countries. For more information visit at CSLBehring.com/Vita and follow us on Twitter.com/CSLBehring.
"We do everything we do with passion - and we do it for life." (Stefan Drager, Executive Board Chairman)
As an international leader in medical and safety technology, Drager develops innovative equipment and solutions that people all over the world over trust when lives are on the line. Our medical division's product range covers anesthesia workstations, ventilation equipment for intensive care, emergency, neonatal and mobile ventilation units, warming therapy equipment for infants, patient monitoring equipment, IT solutions, architectural systems and gas management systems.
Edwards Lifesciences has been advancing the care of the acutely ill for over 40 years. We are focused on helping clinicians enhance knowledge and standardize practice to improve the quality and efficiency of care. Edwards is dedicated to providing evidence-based medicine programs such as the Enhanced Surgical Recovery Program that facilitates the implementation and compliance of protocolized care in the OR in order to reduce post-surgical complications. Edwards also offers a range of advanced monitoring tools – including noninvasive to minimally-invasive hemodynamic monitoring and continuous glucose monitoring – expansive educational resources, and clinical support to ensure sustained compliance.
Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in most important countries of Latin America and Asia Pacific. Within I.V. generic drugs, Fresenius Kabi counts among the leading suppliers in the U.S. market. All over the world more than 24,000 employees are committed to improving the quality of life of critically and chronically ill patients with innovative products for patients in hospitals and outpatients.
Fresenius Medical Care (FME) offers services & products in more than 120 countries and cares for more than 310,000 patients in our global network of more than 3,600 dialysis clinics. At the same time, we operate 37 production sites on all continents, to provide dialysis products such as dialysis machines, dialyzers and related disposables.
Offering a variety of therapies, Fresenius Medical Care provides efficient treatment of acute kidney injury to fit each patient's specific needs. Besides the several options for CRRT, Fresenius Medical Care also provides options for plasmapheresis and therapeutic apheresis.
Therapeutic apheresis is a therapy for removing pathogenic substances from blood using filters and adsorbers. With a portfolio of different adsorbers and long-standing expertise in extracorporeal procedures, Fresenius Medical Care delivers a combination of quality and flexible treatment alternatives, designed to treat a wide range of diseases and increase the patient’s quality of life.
In January 2017, Fresenius Medical Care acquired the Xenios company. Xenios offers minimally invasive disposable lung and heart therapies on one single platform. This acquisition is an opportunity to expand FME’s position as the global leader in extracorporeal organ support.
Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. A key medical technology innovator, Masimo is responsible for the invention of award-winning noninvasive technologies that are revolutionizing patient monitoring, including Masimo SET® pulse oximetry, Masimo Rainbow Pulse CO-Oximetry and new Masimo noninvasive and continuous total hemoglobin (SpHb™) monitoring technology. The recent introduction of the first-and-only FDA-cleared technology that noninvasively and continuously measures total hemoglobin without a painful needle stick and invasive blood draw is expected to open new markets and significantly expand the company’s growth opportunities.